Free Trial
NYSE:KDMN

Kadmon (KDMN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$9.50
$9.50
50-Day Range
$9.50
$9.50
52-Week Range
$3.19
$9.50
Volume
1,052 shs
Average Volume
5.11 million shs
Market Capitalization
$1.70 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KDMN stock logo

About Kadmon Stock (NYSE:KDMN)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

KDMN Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive KDMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kadmon and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Pharmaceutical Preparation Manufacturing
Sub-Industry
N/A
CIK
N/A
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.70 billion
Optionable
Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

KDMN Stock Analysis - Frequently Asked Questions

When did Kadmon IPO?

Kadmon (KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What other stocks do shareholders of Kadmon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kadmon investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Organigram (OGI), KushCo (KSHB), Zosano Pharma (ZSAN) and Bionano Genomics (BNGO).

This page (NYSE:KDMN) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners